Home
Hande Sciences

Hande Sciences Market Share Analysis for February 2026

a world-class cdmo company, provide high-quality r&d and production service for global pharmaceutical companies.

Industry: N/A

Domainhandesciences.com

Year Founded2007

Employees201 - 500

Annual Revenue--

Hande Sciences

Hande Sciences (including company regionals)

handesciences.com

See more website traffic and engagement information

Total visits to Hande Sciences's top domains

Understand Hande Sciences market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

handesciences.com46

See more with Sales Intelligence

Avg. visit duration in Hande Sciences's top domains

Analyze Hande Sciences engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

handesciences.com--

See more with Sales Intelligence

Avg. pageviews on Hande Sciences's top domains

See how Hande Sciences keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

handesciences.com1.01

See more with Sales Intelligence

Hande Sciences top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Hande Sciences

These are the website technologies, by industry, used by Hande Sciences top domains

Mobile (2)

Meta Viewport

Content Management System (1)

Hugo

News & Signals from Hande Sciences

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsQualigen, Inc. partnered with Hande Sciences on Jul 6th '22.Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its partnership with China-based Hande Sciences (“Hande”) to conduct manufacturing scale-up activities to support the Company’s IND-enabling good laboratory practice (GLP) studies for its lead therapeutic program, QN-302.